Dupilumab efficacy in children with uncontrolled type 2 asthma with baseline high/medium ICS dose
J. Maspero ( Buenos Aires, Argentina), M. Antila (Sorocaba, Sao Paulo, Brazil), N. Jain (Gilbert, Arizona, United States), A. Deschildre (Lille, France), L. Bacharier (Nashville, Tennessee, United States), A. Altincatal (Cambridge, Massachusetts, United States), E. Laws (Bridgewater, New Jersey, United States), B. Akinlade (Tarrytown, New York, United States), S. Siddiqui (Tarrytown, New York, United States), J. Jacob-Nara (Bridgewater, New Jersey, United States), Y. Deniz (Tarrytown, New York, United States), P. Rowe (Bridgewater, New Jersey, United States), D. Lederer (Tarrytown, New York, United States), M. Hardin (Cambridge, Massachusetts, United States)
Source: International Congress 2022 – New insights into paediatric asthma diagnosis and management of severe asthma
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Maspero ( Buenos Aires, Argentina), M. Antila (Sorocaba, Sao Paulo, Brazil), N. Jain (Gilbert, Arizona, United States), A. Deschildre (Lille, France), L. Bacharier (Nashville, Tennessee, United States), A. Altincatal (Cambridge, Massachusetts, United States), E. Laws (Bridgewater, New Jersey, United States), B. Akinlade (Tarrytown, New York, United States), S. Siddiqui (Tarrytown, New York, United States), J. Jacob-Nara (Bridgewater, New Jersey, United States), Y. Deniz (Tarrytown, New York, United States), P. Rowe (Bridgewater, New Jersey, United States), D. Lederer (Tarrytown, New York, United States), M. Hardin (Cambridge, Massachusetts, United States). Dupilumab efficacy in children with uncontrolled type 2 asthma with baseline high/medium ICS dose. 2950
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|